Brief: Denali Therapeutics Announces U.S. FDA Breakthrough Therapy Designation Granted To Tividenofusp Alfa For The Treatment Of Hunter Syndrome (MPS II)
08/01/2025 13:53
Jan 8 (Reuters) - Denali Therapeutics Inc DNLI.O :
* DENALI THERAPEUTICS ANNOUNCES U.S. FDA BREAKTHROUGH
THERAPY
DESIGNATION GRANTED TO TIVIDENOFUSP ALFA FOR THE TREATMENT OF
HUNTER SYNDROME (MPS II)
* DENALI THERAPEUTICS INC - EXPECTS TO SUBMIT BLA FOR
TIVIDENOFUSP
ALFA IN EARLY 2025
Source text: urn:newsml:reuters.com:*:nGNX1hSTYb
Further company coverage: DNLI.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Denali Therapeutics
See all newsDenali Therapeutics Inc. reports results for the quarter ended June 30 - Earnings Summary
Denali Therapeutics Q2 net loss widens as AVLAYAH launch costs rise
Biogen's Alzheimer's drug lowers toxic protein, but results were mixed
U.S. STOCKS ON THE MOVE-Sweetgreen, Dell Technologies, Peloton Interactive
U.S. STOCKS ON THE MOVE-IMAX, Novo Nordisk, PC makers